Potential SP Valuation of AT1 - 80 cents to 1.30/share, page-54

Some of the key points from the interview.

John Kelly: Rapid test co was done through a chemistry kit, Atomo have re-engineered a consumer friendly device fit for purpose.Agreement in 130 countires for HIV testing.Covid19 and pregnancy test with NG Biotech.NG biotech has a rapid CV19 test that is a validated rapid test will tell you if you have an antibody response - it is a population management perspective will be very effective. Only company in the world with a self test for CV19. Single use disposable test and not reusable.

Forward: listing to expand our production and to roll out HIV globally, CV19 came along at the same time as we were going to market certainly for the near term looking to sell everything we can make and scale up capacity and making sure that our technology can be deployed globally for CV19 while we continue to bring on the HIV business and bring on other clinical applications. Capacity is key we are scaling up our manufacturing capabilities quite aggressively now to deliver on CV19, and that is something that is in process and will be completed later this year. From an execution perspective making that happen is critical for us and just from a revenue growth but also for making sure that we can have an impact on CV19. R&D and corporate is run out of Sydney. Outsourced manufacturing with an Australian company that has a facility in China and the US and have opened up our own faciltiy in Cape Town SA, specifically for HIV test manufacture. A global company headquartered and run out of Sydney.

@hotuna AT1 has a plastic shell for single use testing, NG Biotech has the strip to test CV19 antibody presence. Combined they have the only user friendly single use self test device for the virus. As John Kelly says this will play a big role in disease management.

JK clearly states that the their first goal is to sell everything that they can make. The next step is to scale up capacity which he says they will do later this year.

It is quite clear, unequivocally so, that JK believes that AT1 will play a role in managing CV19: "making sure that our technology can be deployed globally for CV19".

gla